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Session: Regenerative Medicine 109incubated for 24 hours. Pre- and post-iron sucrose labelled ASCS were evaluated
for cell surface immunophenotypes (CD73, CD90, CD105, CD 34, CD45 and HLA-
DR) and stained with 5%Prussian blue solution for proved ferric iron deposition.
Cell viability was assessed in hemocytometer after tripsinization by Trypan blue so-
lution. Chondrogenic-, adipogenic- and osteogenic differentiation of ASCs were
evaluated. Labelled-ASCs were titrated into 5x102, 5x103, 5x104, 5x105, 5x106
and 5x107 cells/ml and were determined their intensity using 3T MRI.
Results: The expression markers of iron sucrose labelled ASCs on flow cytometry
were equivalent with control. Mean of cell viability was 94.10 percent. Iron sucrose
labelled ASCs were proved for ferric iron uptake and cell differentiation in each
linage by specific staining solution. We were able to detected iron intensity start-
ing from 5x105 cells/microtube and increasing intensity in 5x106 and 5x107 cells/
microtube, respectively.
Conclusion: Iron sucrose incubation is an alternative safety method for ASCs label-
ling and tracking them after treatment by MRI. Clinicians and researchers may col-
lecting the location of ASCs engraftment without secondary surgical operation for
tissue sampling. Furthermore, animal studies are required to prove this method
before clinical application.
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Tissue engineered bone grafts (TEBG) using mesenchymal stem cells (MSCs)
demonstrate great potential for large bone defect treatment. However, the
current MSC expansion technique and the multi-step TEBG construction strategy
are harassed with many problems such as complicated and labour-intensive
procedures, high risk of contamination, and repeated trypsinisation, limiting the
clinical application of bone tissue engineering (BTE) technology. Microcarriers
may present a promising approach to address these problems, but currently
available microcarriers are either non-implantable or insufficient of biomimetic
potential to promote effective cell growth and function. In the current study,
we used demineralized bone matrix (DBM) to develop a biomimetic and
implantable microcarrier (DBM-MC), which could preserve the essential
biochemical composition, architecture, and surface topography of natural
bone tissue and provide the biomimetic matrix microenvironment for cell
adhesion, proliferation, and differentiation. Furthermore, we established a
DBM-MC based integrated TEBG fabrication strategy to seamlessly integrate the
multiple procedures including cell seeding, expansion, and osteogenic priming
under a continuous dynamic rotation condition. When benchmarked with
Cytodex 3, a widely used microcarrier, the DBM-MC shared similar density and
supported efficient cell adhesion and fast cell proliferation with the MSC
characteristics well-maintained. However, when expanded in vitro and
implanted in vivo ectopically, the MSC mediated DBM-MC constructs achieved
much more new bone formation with good vascularisation throughout the dense
bone tissue; whereas, MSC mediated Cytodex 3 constructs experienced limited
bone formation with scarce vascular networks and empty necrotic cavities in
the core region. Moreover, the mTEBG constructs generated via this integrated
system was used for critical sized cranial defect treatment and achieved suc-
cessful defect bridging at three months with two folds more bone regeneration.
The biomimetic and implantable DBM-MC based integrated system can provideFigure 1 Hypoxia- and chondrocyte-specific marker gene expression. Accepted phy
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*** p < 0.001.an enclosed, large-scale, reduced trypsinisation, semi-automatic, and single-
step fabrication process to generate highly effective mTEBGs with outstanding
osteogenic and angiogenic efficacy, thus demonstrating great potential for the
clinical application of BTE.
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Background: Adult chondrocytes experience a hypoxic environment in vivo, which
is also referred to as physioxia (i.e., physiologically deprived oxygen pressure).
Positive effects on extracellular matrix (ECM) synthesis have been reported for
culturing chondrocytes from different species and origins under low oxygen ten-
sions that more closely resemble the in vivo situation. During re-differentiation
of expanded articular chondrocytes, physioxia during in vitro culture increased
the collagen type II expression. However, the mechanism by which physioxia en-
hances re-differentiation is still incompletely understood. We employed micro-
bioreactor technology to shed light into the contribution of the TGF-b superfamily
signalling ligands during chondrocyte differentiation under physioxic conditions in
vitro.
Subjects and Methods: De-differentiated chondrocytes in alginate were cultured
for 48 hours under physioxic (1% pO2) or normoxic (20%) conditions, using special-
ised bioreactor technology. Gene expression of chondrocyte-specific markers
(e.g., SOX9, COL2A1) as well as established hypoxia-controlled genes (e.g.,
PHD3, VEGFA, GDF10, HAS2) and components of the TGF-b superfamily signalling
pathways were analysed by real-time qRT-PCR and protein expression (Western
blot) after 48 hours. In addition, the conditions were combined with TGF-b super-
family ligand-specific RNAi (Sigma-Mission shRNA library) as well as selected phar-
macological TGF-b superfamily receptor inhibitors.
Results: Physioxia showed robust up-regulation of selected hypoxia-specific
marker genes. Furthermore, well-established chondrocyte-specific markers like
SOX9 and type II collagen were up-regulated (Fig. 1). From the different TGF-b iso-
forms, only one was selectively regulated by physioxic in vitro conditions on mRNA
and protein levels. In addition, physioxia also up-regulated both activin receptor-
like kinases, ALK1 and ALK5, while respective type II and III receptors appeared un-
responsive. Physioxia-induced type II collagen (COL2) expression was abrogated by
TGF-b isoform-specific RNAi. ALK5 inhibition showed a similar effect (data not
shown).
Discussion and Conclusion: In the present study, we used a sophisticated biore-
actor system to stringently feedback-control dissolved oxygen concentration in
the culture media of 3D-cultured chondrocytes in vitro. This, to show that extreme
physioxia (i.e., 1% pO2, resembling deep layer articular chondrocytes) induces
COL2 expression. Physioxia further appeared to facilitate TGF-b signalling in these
cells through ALK5 as evident from pharmacological inhibition. In summary, our
findings strongly suggest that low level hypoxia-induced TGF-b expression in human
articular chondrocytes in vitro is responsible for a subsequent induction of type IIsioxia-induced genes in chondrocytes (A) next to two key markers of chondrocyte
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